 Outlook Therapeutics, Inc. OTLK the Company, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering priced at-the-market under Nasdaq rules, of 7,598,426 shares of its common stock, at a combined purchase price of 1.016 per share and associated unregistered warrant, for aggregate gross proceeds of approximately 7.72 million. The Company also agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 3,799,213 shares of its common stock. 